Physician profile
Magdoline Daas
NPI 1598726168
$922.85
in general payments reported to CMS, 2019-2025
14 companies · $31.64 in 2025
The $31.64 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $57.11 · 2021: $83.36 · 2022: $67.17 · 2023: $49.41 · 2024: $420 · 2025: $31.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $434.19 | 2021-2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $195.15 | 2019-2022 | |
| Abbvie INC. | $61.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $57.52 | 2019-2024 | Rexulti |
| Lundbeck LLC | $29.14 | 2020-2022 | |
| Axsome Therapeutics, INC. | $20.96 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $19.17 | 2019 | |
| Bioxcel Therapeutics, INC. | $19.13 | 2023 | Igalmi |
| Alkermes, INC. | $17.48 | 2023 | Aristada, Lybalvi |
| Shire North American Group INC | $15.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.80 | 2023 | Uzedy |
| Ironshore Pharmaceuticals INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdoline Daas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.